RNA nanoparticles derived from three-way junction of Phi29 motor pRNA are resistant to I-125 and Cs-131 radiation

Nucleic Acid Therapeutics

Volumn 25, Issue 4, 2015, Pages 188-197

  Li, Hui ^a,b   Rychahou, Piotr G ^c   Cui, Zheng ^b   Pi, Fengmei ^a,b   Evers, B Mark ^d   Shu, Dan ^a,b,d   Guo, Peixuan ^a,b,d   Luo, Wei ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CESIUM 131; IODINE 125; NANOPARTICLE; OLIGONUCLEOTIDE; PACKAGING RNA; PLASMID DNA; RNA; RNA NANOPARTICLE; UNCLASSIFIED DRUG; UREA; CESIUM; FOLATE RECEPTOR; FOLIC ACID; RADIOACTIVE IODINE; VIRUS RNA;

ARTICLE; BACILLUS PHAGE PHI29; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA PACKAGING; HT 29 CELL LINE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RNA ANALYSIS; ANIMAL; BACILLUS PHAGE; CHEMISTRY; COLON TUMOR; CONFORMATION; DIAGNOSTIC IMAGING; DRUG SCREENING; HT-29 CELL LINE; HUMAN; KB CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NUDE MOUSE; PATHOLOGY; PROCEDURES; RNA STABILITY; SCINTISCANNING; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BACILLUS PHAGES; CESIUM RADIOISOTOPES; COLONIC NEOPLASMS; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HT29 CELLS; HUMANS; INJECTIONS, SUBCUTANEOUS; IODINE RADIOISOTOPES; KB CELLS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NUCLEIC ACID CONFORMATION; RADIONUCLIDE IMAGING; RNA STABILITY; RNA, VIRAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937694403     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0525     Document Type: Article

References (62)

1. Hanahan D, and R.A. Weinberg. (2000). The hallmarks of cancer. Cell 100: 57-70
2. Hanahan D, and R.A. Weinberg. (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674
3. Jemal A, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman. (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90
4. Economic Impact of Cancer. www.cancer.org/cancer/cancerbasics/economic-impact-of-cancer. Last accessed date: April 20, 2015
5. Baskar R, K.A. Lee, R. Yeo, and K.W. Yeoh. (2012). Cancer, and radiation therapy: current advances, and future directions. Int J Med Sci 9: 193-199
6. Bloomer WD, and S. Hellman. (1975). Normal tissue responses to radiation therapy. N Engl J Med 293: 80-83
7. Bentzen SM. (2006). Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6: 702-713
8. Spencer RP, R.H Seevers, and A.M. Friedman, eds. (1987). Radionuclides in Therapy. CRC Press, Boca Raton, FL
9. Peer D, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760
10. Davis ME, Z.G. Chen, and D.M. Shin. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782
11. Brannon-Peppas L, and J.O. Blanchette. (2004). Nanoparticle, and targeted systems for cancer therapy. Adv Drug Deliv Rev 56: 1649-1659
12. Lee H, A.K. Lytton-Jean, Y. Chen, K.T. Love, A.I. Park, E.D. Karagiannis, A. Sehgal, W. Querbes, C.S. Zurenko, et al. (2012). Molecularly self-Assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 7: 389-393
13. Guo P. (2010). The emerging field of RNA nanotechnology. Nat Nanotechnol 5: 833-842
14. Shu Y, F. Pi, A. Sharma, M. Rajabi, F. Haque, D. Shu, M. Leggas, B.M. Evers, and P. Guo. (2014). Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev 66C: 74-89
15. Kairemo K, P. Erba, K. Bergstrom, and E. Pauwels. (2008). Nanoparticles in cancer. Curr Radiopharm 1: 30-36
16. Cai W, T. Gao, H. Hong, and J. Sun. (2008). Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl 1: 17-32
17. Zhang L, H. Chen, L. Wang, T. Liu, J. Yeh, G. Lu, L. Yang, and H. Mao. (2010). Delivery of therapeutic radioisotopes using nanoparticle platforms: potential benefit in systemic radiation therapy. Nanotechnol Sci Appl 3: 159-170
18. Shu Y, M. Cinier, D. Shu, and P. Guo. (2011). Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA, and other therapeutics to targeted cells. Methods 54: 204-214
19. Haque F, D. Shu, Y. Shu, L. Shlyakhtenko, P. Rychahou, M. Evers, and P. Guo. (2012). Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today 7: 245-257
20. Shu Y, F. Haque, D. Shu, W. Li, Z. Zhu, M. Kotb, Y. Lyubchenko, and P. Guo. (2013). Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA 19: 766-777
21. Guo P, C. Zhang, C. Chen, M. Trottier, and K. Garver. (1998). Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell 2: 149-155
22. Guo P, F. Haque, B. Hallahan, R. Reif, and H. Li. (2012). Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther 22: 226-245
23. Bindewald E, K. Afonin, L. Jaeger, and B.A. Shapiro. (2011). Multistrand RNA secondary structure prediction, and nanostructure design including pseudoknots. ACS Nano 5: 9542-9551
24. Ye X, M. Hemida, H.M. Zhang, P. Hanson, Q. Ye, and D. Yang. (2012). Current advances in Phi29 pRNA biology, and its application in drug delivery. Wiley Interdiscip Rev RNA 3: 469-481
25. Afonin KA, E.O. Danilov, I.V. Novikova, and N.B. Leontis. (2008). TokenRNA: A new type of sequence-specific, label-free fluorescent biosensor for folded RNA molecules. Chembiochem 9: 1902-1905
26. Shu D, W.D. Moll, Z. Deng, C. Mao, and P. Guo. (2004). Bottom-up assembly of RNA arrays, and superstructures as potential parts in nanotechnology. Nano Lett 4: 1717-1723
27. Shu D, Y. Shu, F. Haque, S. Abdelmawla, and P. Guo. (2011). Thermodynamically stable RNA three-way junctions for constructing multifuntional nanoparticles for delivery of therapeutics. Nat Nanotechnol 6: 658-667
28. Abdelmawla S, S. Guo, L. Zhang, S. Pulukuri, P. Patankar, P. Conley, J. Trebley, P. Guo, and Q.X. Li. (2011). Pharmacological characterization of chemically synthesized monomeric pRNA nanoparticles for systemic delivery. Mol Ther 19: 1312-1322
29. Cerchia L, P.H. Giangrande, J.O. McNamara, and F.V. de. (2009). Cell-specific aptamers for targeted therapies. Methods Mol Biol 535: 59-78
30. Guo P, and M. Trottier. (1994). Biological, and biochemical properties of the small viral RNA (pRNA) essential for the packaging of the double-stranded DNA of phage j29. Semin Virol 5: 27-37
31. Rajendran JG. (2007). Therapeutic radioisotopes. In: Nuclear Medicine Therapy. Early J, and W. Brenner, eds. Informa Healthcare, New York, NY, pp 9-20
32. Hoefnagel CA. (1998). Radionuclide cancer therapy. Ann Nucl Med 12: 61-70
33. Sofou S. (2008). Radionuclide carriers for targeting of cancer. Int J Nanomedicine 3: 181-199
34. Hamoudeh M, M.A. Kamleh, R. Diab, and H. Fessi. (2008). Radionuclides delivery systems for nuclear imaging, and radiotherapy of cancer. Adv Drug Deliv Rev 60: 1329-1346
35. Williams LE, G.L. DeNardo, and R.F. Meredith. (2008). Targeted radionuclide therapy. Med Phys 35: 3062-3068
36. Lyubchenko YL, and L.S. Shlyakhtenko. (2009). AFM for analysis of structure, and dynamics of DNA, and protein-DNA complexes. Methods 47: 206-213
37. Pieken WA, D.B. Olsen, F. Benseler, H. Aurup, and F. Eckstein. (1991). Kinetic characterization of ribonucleaseresistant 2¢-modified hammerhead ribozymes. Science 253: 314-317
38. Kawasaki AM, M.D. Casper, S.M. Freier, E.A. Lesnik, M.C. Zounes, L.L. Cummins, C. Gonzalez, and P.D. Cook. (1993). Uniformly modified 2¢-deoxy-2¢-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity, and specificity for RNA targets. J Med Chem 36: 831-841
39. Sabahi A, J. Guidry, G.B. Inamati, M. Manoharan, and P. Wittung-Stafshede. (2001). Hybridization of 2¢-ribose modified mixed-sequence oligonucleotides: thermodynamic, and kinetic studies. Nucleic Acids Res 29: 2163-2170
40. Liu J, S. Guo, M. Cinier, L.S. Shlyakhtenko, Y. Shu, C. Chen, G. Shen, and P. Guo. (2011). Fabrication of stable, and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano 5: 237-246
41. Meigooni AS, J.L. Hayes, H. Zhang, and K. Sowards. (2002). Experimental, and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE 125I brachytherapy source. Med Phys 29: 2152-2158
42. Prestidge BR, W.S. Bice, I. Jurkovic, E. Walker, S. Marianne, and A. Sadeghi. (2005). Cesium-131 permanent prostate brachytherapy: an initial report. Int J Radiat Oncol Biol Phys 63: S336-S337
43. Ravi A, B.M. Keller, and J. Pignol. (2011). Evaluation of the radiation safety of using Cs-131 seeds for permanent breast seed implantation. Int J Radiat Oncol Biol Phys 81: S720-S721
44. Yan W, S. Trichter, A. Sabbas, A.G. Wernicke, D. Nori, KSC Chao, and B. Parashar. (2010). Cesium-131 brachytherapy for lung cancer: dosimetric, safety considerations, and initial experience. Int J Radiat Oncol Biol Phys 78: S540-S541
45. Rivard MJ, C.S. Melhus, S. Sioshansi, and J. Morr. (2008). The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using Pd-103, I-125, and Cs-131. Brachytherapy 7: 327-335
46. Luo W, J. Molloy, P. Aryal, J. Feddock, and M. Randall. (2014). Determination of prescription dose for Cs-131 permanent implants using the BED formalism including resensitization correction. Med Phys 41: 024101
47. Wooten CE, M. Randall, J. Edwards, P. Aryal, W. Luo, and J. Feddock. (2014). Implementation, and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies. Gynecol Oncol 133: 268-273
48. Murphy MK, R.K. Piper, L.R. Greenwood, M.G. Mitch, P.J. Lamperti, S.M. Seltzer, M.J. Bales, and M.H. Phillips. (2004). Evaluation of the new cesium-131 seed for use in lowenergy x-ray brachytherapy. Med Phys 31: 1529-1538
49. Rosenbaum V, and D. Riesner. (1987). Temperaturegradient gel-electrophoresis-Thermodynamic analysis of nucleic-Acids, and proteins in purified form, and i.n. cellularextracts. Biophys Chem 26: 235-246
50. Binzel DW, E.F. Khisamutdinov, and P. Guo. (2014). Entropydriven one-step formation of Phi29 pRNA 3WJ from three RNA fragments. Biochemistry 53: 2221-2231
51. Guo P. (2005). RNA nanotechnology: engineering, assembly, and applications in detection, gene delivery, and therapy. J Nanosci Nanotechnol 5: 1964-1982
52. Guo P, and F Haque, eds. (2013). RNA Nanotechnology, and Therapeutics. CRC Press, Boca Raton, FL
53. Khisamutdinov EF, D.L. Jasinski, and P. Guo. (2014). RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape, and stoichiometry. ACS Nano 8: 4771-4781
54. Jasinski D, E.F. Khisamutdinov, Y.L. Lyubchenko, and P. Guo. (2014). Physicochemically tunable poly-functionalized rna square architecture with fluorogenic, and ribozymatic properties. ACS Nano 8: 7620-7629
55. Khisamutdinov E, H. Li, D. Jasinski, J. Chen, J. Fu, and P. Guo. (2014). Enhancing immunomodulation on innate immunity by shape transition among RNA triangle, square, and pentagon nanovehicles. Nucleic Acids Res 42: 9996-10004
56. Lee TJ, F. Haque, D. Shu, J.Y. Yoo, H. Li, R.A. Yokel, C. Horbinski, T.H. Kim, S-H Kim, et al. (2015). RNA nanoparticles as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget [Epub ahead of print
57. Afonin KA, M. Viard, I. Kagiampakis, C.L. Case, M.A. Dobrovolskaia, J. Hofmann, A. Vrzak, M. Kireeva, W.K. Kasprzak, and V.N. KewalRamani. (2014). Triggering of RNA interference with RNA-RNA, RNA-DNA, and DNA-RNA nanoparticles. ACS Nano 9: 251-259
58. Afonin KA, M. Viard, A.Y. Koyfman, A.N. Martins, W.K. Kasprzak, M. Panigaj, R. Desai, A. Santhanam, W.W. Grabow, et al. (2014). Multifunctional RNA nanoparticles. Nano Lett 14: 5662-5671
59. Jensen SA, E.S. Day, C.H. Ko, L.A. Hurley, J.P. Luciano, F.M. Kouri, T.J. Merkel, A.J. Luthi, P.C. Patel, et al. (2013). Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med 5: 209ra152
60. Lee FT, A. Rigopoulos, C. Hall, K. Clarke, S.H. Cody, F.E. Smyth, Z. Liu, M.W. Brechbiel, N. Hanai, et al. (2001). Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res 61: 4474-4482
61. Zinn KR, T.R. Chaudhuri, V.N. Krasnykh, D.J. Buchsbaum, N. Belousova, W.E. Grizzle, D.T. Curiel, and B.E. Rogers. (2002). Gamma camera dual imaging with a somatostatin receptor, and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 223: 417-425
62. Meng LJ, G. Fu, E.J. Roy, B. Suppe, and C.T. Chen. (2009). An ultrahigh resolution SPECT system for I-125 mouse brain imaging studies. Nucl InstrumMethods Phys Res A 600: 498-505